Protective Effects of Interleukin‐1 Inhibition With Anakinra in Mouse Models of Ischemic Stroke With and Without Reperfusion
Background Severe brain ischemia is associated with life‐threatening edema and inflammation. Interleukin‐1 is a crucial mediator of inflammation, and its blockade showed benefits in experimental stroke. We studied anakinra, a modified recombinant human interleukin‐1 receptor antagonist, in mouse mod...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-05-01
|
| Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| Subjects: | |
| Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.124.040474 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850271255718002688 |
|---|---|
| author | Nerea Chaparro‐Cabanillas Alicia Aliena‐Valero Jordi Pedragosa Leire Pedrosa Milagros Honores Mercè Rossinyol‐Boladeres Juan B. Salom Ángel Chamorro Juan I. Arostegui Xabier Urra Carles Justicia Anna M. Planas |
| author_facet | Nerea Chaparro‐Cabanillas Alicia Aliena‐Valero Jordi Pedragosa Leire Pedrosa Milagros Honores Mercè Rossinyol‐Boladeres Juan B. Salom Ángel Chamorro Juan I. Arostegui Xabier Urra Carles Justicia Anna M. Planas |
| author_sort | Nerea Chaparro‐Cabanillas |
| collection | DOAJ |
| description | Background Severe brain ischemia is associated with life‐threatening edema and inflammation. Interleukin‐1 is a crucial mediator of inflammation, and its blockade showed benefits in experimental stroke. We studied anakinra, a modified recombinant human interleukin‐1 receptor antagonist, in mouse models of moderate to severe ischemia/reperfusion and large hemispheric infarctions. Due to anakinra's short half‐life, we used a novel subcutaneous infusion protocol and tested 2 drug doses. Methods and Results We performed transient or permanent intraluminal middle cerebral artery occlusion (MCAo) in male C57BL/6J and Balb/c mice, the latter of which have poorer collaterals. Mice received a subcutaneous anakinra bolus (24 mg/kg), followed by continuous infusion of either 24 or 120 mg/kg per day, starting at reperfusion or 15 minutes after permanent MCAo. We evaluated acute (24 hours/48 hours) infarct volume and edema by magnetic resonance imaging, neurological function, and inflammatory responses. The mortality rate tended to be higher in Balb/c compared with C57BL/6J mice. In both strains, prolonged ischemia expanded the infarct size, with intraluminal permanent MCAo resulting in larger hemispheric infarctions and edema than transient MCAo. The high dose of anakinra reduced infarct volume and inflammation in C57BL/6 mice and improved the functional deficits in Balb/c mice following transient MCAo. It also showed a trend toward reducing infarction and edema after permanent MCAo in C57BL/6 mice. Conclusions The study demonstrates that a high dose of anakinra improves outcomes in mouse models of moderate infarction following ischemia/reperfusion, whereas its effect was less pronounced in a malignant hemispheric infarction model without reperfusion, where only a nonsignificant trend toward protection was observed. |
| format | Article |
| id | doaj-art-4179168e6d934dffb5f396d2e1d28cae |
| institution | OA Journals |
| issn | 2047-9980 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| spelling | doaj-art-4179168e6d934dffb5f396d2e1d28cae2025-08-20T01:52:18ZengWileyJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease2047-99802025-05-0114910.1161/JAHA.124.040474Protective Effects of Interleukin‐1 Inhibition With Anakinra in Mouse Models of Ischemic Stroke With and Without ReperfusionNerea Chaparro‐Cabanillas0Alicia Aliena‐Valero1Jordi Pedragosa2Leire Pedrosa3Milagros Honores4Mercè Rossinyol‐Boladeres5Juan B. Salom6Ángel Chamorro7Juan I. Arostegui8Xabier Urra9Carles Justicia10Anna M. Planas11Departament de Neurociències i Terapèutica Experimental Institut d’Investigacions Biomèdiques de Barcelona (IIBB), CSIC Barcelona SpainUnidad Mixta de Investigación Cerebrovascular Instituto de Investigación Sanitaria La Fe—Universidad de Valencia València SpainDepartament de Neurociències i Terapèutica Experimental Institut d’Investigacions Biomèdiques de Barcelona (IIBB), CSIC Barcelona SpainDepartament de Neurociències i Terapèutica Experimental Institut d’Investigacions Biomèdiques de Barcelona (IIBB), CSIC Barcelona SpainDepartament de Neurociències i Terapèutica Experimental Institut d’Investigacions Biomèdiques de Barcelona (IIBB), CSIC Barcelona SpainDepartament de Neurociències i Terapèutica Experimental Institut d’Investigacions Biomèdiques de Barcelona (IIBB), CSIC Barcelona SpainUnidad Mixta de Investigación Cerebrovascular Instituto de Investigación Sanitaria La Fe—Universidad de Valencia València SpainFundació de Recerca Clínic Barcelona‐IDIBAPS Barcelona SpainUniversitat de Barcelona Barcelona SpainFundació de Recerca Clínic Barcelona‐IDIBAPS Barcelona SpainDepartament de Neurociències i Terapèutica Experimental Institut d’Investigacions Biomèdiques de Barcelona (IIBB), CSIC Barcelona SpainDepartament de Neurociències i Terapèutica Experimental Institut d’Investigacions Biomèdiques de Barcelona (IIBB), CSIC Barcelona SpainBackground Severe brain ischemia is associated with life‐threatening edema and inflammation. Interleukin‐1 is a crucial mediator of inflammation, and its blockade showed benefits in experimental stroke. We studied anakinra, a modified recombinant human interleukin‐1 receptor antagonist, in mouse models of moderate to severe ischemia/reperfusion and large hemispheric infarctions. Due to anakinra's short half‐life, we used a novel subcutaneous infusion protocol and tested 2 drug doses. Methods and Results We performed transient or permanent intraluminal middle cerebral artery occlusion (MCAo) in male C57BL/6J and Balb/c mice, the latter of which have poorer collaterals. Mice received a subcutaneous anakinra bolus (24 mg/kg), followed by continuous infusion of either 24 or 120 mg/kg per day, starting at reperfusion or 15 minutes after permanent MCAo. We evaluated acute (24 hours/48 hours) infarct volume and edema by magnetic resonance imaging, neurological function, and inflammatory responses. The mortality rate tended to be higher in Balb/c compared with C57BL/6J mice. In both strains, prolonged ischemia expanded the infarct size, with intraluminal permanent MCAo resulting in larger hemispheric infarctions and edema than transient MCAo. The high dose of anakinra reduced infarct volume and inflammation in C57BL/6 mice and improved the functional deficits in Balb/c mice following transient MCAo. It also showed a trend toward reducing infarction and edema after permanent MCAo in C57BL/6 mice. Conclusions The study demonstrates that a high dose of anakinra improves outcomes in mouse models of moderate infarction following ischemia/reperfusion, whereas its effect was less pronounced in a malignant hemispheric infarction model without reperfusion, where only a nonsignificant trend toward protection was observed.https://www.ahajournals.org/doi/10.1161/JAHA.124.040474anakinracytokinesedemainflammationischemic strokemalignant infarction |
| spellingShingle | Nerea Chaparro‐Cabanillas Alicia Aliena‐Valero Jordi Pedragosa Leire Pedrosa Milagros Honores Mercè Rossinyol‐Boladeres Juan B. Salom Ángel Chamorro Juan I. Arostegui Xabier Urra Carles Justicia Anna M. Planas Protective Effects of Interleukin‐1 Inhibition With Anakinra in Mouse Models of Ischemic Stroke With and Without Reperfusion Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease anakinra cytokines edema inflammation ischemic stroke malignant infarction |
| title | Protective Effects of Interleukin‐1 Inhibition With Anakinra in Mouse Models of Ischemic Stroke With and Without Reperfusion |
| title_full | Protective Effects of Interleukin‐1 Inhibition With Anakinra in Mouse Models of Ischemic Stroke With and Without Reperfusion |
| title_fullStr | Protective Effects of Interleukin‐1 Inhibition With Anakinra in Mouse Models of Ischemic Stroke With and Without Reperfusion |
| title_full_unstemmed | Protective Effects of Interleukin‐1 Inhibition With Anakinra in Mouse Models of Ischemic Stroke With and Without Reperfusion |
| title_short | Protective Effects of Interleukin‐1 Inhibition With Anakinra in Mouse Models of Ischemic Stroke With and Without Reperfusion |
| title_sort | protective effects of interleukin 1 inhibition with anakinra in mouse models of ischemic stroke with and without reperfusion |
| topic | anakinra cytokines edema inflammation ischemic stroke malignant infarction |
| url | https://www.ahajournals.org/doi/10.1161/JAHA.124.040474 |
| work_keys_str_mv | AT nereachaparrocabanillas protectiveeffectsofinterleukin1inhibitionwithanakinrainmousemodelsofischemicstrokewithandwithoutreperfusion AT aliciaalienavalero protectiveeffectsofinterleukin1inhibitionwithanakinrainmousemodelsofischemicstrokewithandwithoutreperfusion AT jordipedragosa protectiveeffectsofinterleukin1inhibitionwithanakinrainmousemodelsofischemicstrokewithandwithoutreperfusion AT leirepedrosa protectiveeffectsofinterleukin1inhibitionwithanakinrainmousemodelsofischemicstrokewithandwithoutreperfusion AT milagroshonores protectiveeffectsofinterleukin1inhibitionwithanakinrainmousemodelsofischemicstrokewithandwithoutreperfusion AT mercerossinyolboladeres protectiveeffectsofinterleukin1inhibitionwithanakinrainmousemodelsofischemicstrokewithandwithoutreperfusion AT juanbsalom protectiveeffectsofinterleukin1inhibitionwithanakinrainmousemodelsofischemicstrokewithandwithoutreperfusion AT angelchamorro protectiveeffectsofinterleukin1inhibitionwithanakinrainmousemodelsofischemicstrokewithandwithoutreperfusion AT juaniarostegui protectiveeffectsofinterleukin1inhibitionwithanakinrainmousemodelsofischemicstrokewithandwithoutreperfusion AT xabierurra protectiveeffectsofinterleukin1inhibitionwithanakinrainmousemodelsofischemicstrokewithandwithoutreperfusion AT carlesjusticia protectiveeffectsofinterleukin1inhibitionwithanakinrainmousemodelsofischemicstrokewithandwithoutreperfusion AT annamplanas protectiveeffectsofinterleukin1inhibitionwithanakinrainmousemodelsofischemicstrokewithandwithoutreperfusion |